MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

A

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

Search

Revvity Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

97 0.22

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

96.05

Max

97.99

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-8.6M

47M

Pardavimai

-21M

699M

P/E

Sektoriaus vid.

50.057

88.032

Pelnas, tenkantis vienai akcijai

0.4

Dividendų pajamingumas

0.29

Pelno marža

6.675

Darbuotojai

11,000

EBITDA

-14M

181M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+14.96% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.29%

2.26%

Kita Ex Dividend data

2026-01-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-5.8M

11B

Ankstesnė atidarymo kaina

96.78

Ankstesnė uždarymo kaina

97

Naujienos nuotaikos

By Acuity

12%

88%

7 / 374 reitingas Healthcare

Revvity Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-31 22:20; UTC

Pagrindinės rinkos jėgos

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025-12-31 17:31; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025-12-31 16:30; UTC

Pagrindinės rinkos jėgos

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025-12-31 15:19; UTC

Pagrindinės rinkos jėgos

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025-12-31 15:17; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025-12-31 14:37; UTC

Pagrindinės rinkos jėgos

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2026-01-01 23:35; UTC

Rinkos pokalbiai

Gold Rises Amid Geopolitical Risks -- Market Talk

2026-01-01 21:29; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

2026-01-01 21:29; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Sold Stake in JV to Tata Steel

2026-01-01 21:28; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

2026-01-01 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-01 09:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-31 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-31 21:13; UTC

Įsigijimai, susijungimai, perėmimai

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025-12-31 20:40; UTC

Rinkos pokalbiai

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025-12-31 20:22; UTC

Rinkos pokalbiai

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025-12-31 19:50; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025-12-31 19:31; UTC

Rinkos pokalbiai

Precious Metals Cap Off Record Runs -- Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025-12-31 17:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025-12-31 17:16; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025-12-31 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-31 17:00; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025-12-31 15:57; UTC

Įsigijimai, susijungimai, perėmimai

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025-12-31 15:54; UTC

Rinkos pokalbiai

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025-12-31 15:02; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025-12-31 14:40; UTC

Įsigijimai, susijungimai, perėmimai

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025-12-31 14:20; UTC

Rinkos pokalbiai

Crude Futures On Track to End the Year With Losses -- Market Talk

2025-12-31 13:46; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Akcijų palyginimas

Kainos pokytis

Revvity Inc Prognozė

Kainos tikslas

By TipRanks

14.96% į viršų

12 mėnesių prognozė

Vidutinis 111.22 USD  14.96%

Aukščiausias 123 USD

Žemiausias 100 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Revvity Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

5

Pirkti

5

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

7 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat